Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971397 · ClinicalTrials.gov registry record · Phase 1
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02971397 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants.
The verdict
NCT02971397, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, and may be safer for the heart.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
- PROCEDURE Bone Marrow Aspiration and Biopsy
- DRUG Daunorubicin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971397
The ClinicalTrials.gov registry entry for NCT02971397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02971397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02971397 about?
NCT02971397 is a clinical study titled "Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to sto...
What is the current status of trial NCT02971397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-11. Estimated completion is 2018-08-08.
What interventions are being tested in trial NCT02971397?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Bone Marrow Aspiration and Biopsy (PROCEDURE), Daunorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02971397?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.